WO1998024431A1 - Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives - Google Patents
Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives Download PDFInfo
- Publication number
- WO1998024431A1 WO1998024431A1 PCT/JP1997/004306 JP9704306W WO9824431A1 WO 1998024431 A1 WO1998024431 A1 WO 1998024431A1 JP 9704306 W JP9704306 W JP 9704306W WO 9824431 A1 WO9824431 A1 WO 9824431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- compound represented
- substituted pyrrolidine
- halogen atom
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention has a highly selective and potent antagonistic effect on smooth muscle murine force receptor rather than cardiac murine force receptor, and has an irritable bowel syndrome group, diverticulosis, urinary incontinence, esophageal relaxation.
- the present invention relates to a novel N-substituted pyrrolidine derivative useful as a therapeutic agent for a disease involving altered smooth muscle motility and Z or tone such as chronic obstructive airway disease and a method for producing the same.
- Anticholinergics have been used as one of the drugs for irritable bowel syndrome, but they have not been effective enough due to lack of organ selectivity.
- compounds that have a selective antagonism to the smooth muscle musculin receptor have been disclosed (Japanese Patent Application Laid-Open Nos. 2-228360 and 7-149664). However, these compounds do not sufficiently solve the side effects such as mydriasis.
- These compounds have a different structure from the compound of the present invention in which the diphenylalkyl moiety is bonded at the carbon moiety of pyrrolidine and is bonded at the nitrogen moiety.
- An object of the present invention is to provide a novel N-substituted pyrrolidine derivative which has a highly selective and potent antagonistic action on smooth muscle musculin receptor and is effective for treating irritable bowel syndrome and the like.
- the present inventors have conducted intensive studies on a drug having a highly selective and potent antagonism to the smooth muscle musculin receptor and having few side effects of mydriasis.
- New N-substituted pyrrolidi Thus, the present inventors have found that a pharmaceutically acceptable derivative is highly safe and effective for treating irritable bowel syndrome and the like, and completed the present invention.
- the present invention relates to the general formula (1)
- R represents a hydrogen atom, a halogen atom or a lower alkoxy group
- N-substituted pyrrolidine derivative and a pharmaceutically acceptable salt and at least one of them as an active ingredient It is a remedy for gut syndrome.
- the pharmaceutically acceptable salt of the compound represented by the general formula (1) in the present invention includes hydrochloride, hydrobromide, benzenesulfonate, citrate, fumarate, dalconate Acid addition salts such as, lactate, maleate, maleate sulfonate, succinate and tartrate are mentioned.
- lower alkoxy group refers to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, Yushari Sharubitoxi, pentoxy, isopentoxy, Yusharipentoxy. , Neopentoxy, hexoxy, isohexoxy, secondary hexoxy, and evening hexoxy groups, etc .;
- Halogen atom includes fluorine, chlorine, bromine and iodine atoms.
- the compound represented by the general formula (1) can be produced by the following method.
- the compound represented by the general formula (1) can be produced by hydrolyzing the compound represented by the general formula (4).
- the hydrolysis is preferably carried out by heating using an inorganic acid such as concentrated sulfuric acid, preferably at 70 to 110 ° C.
- an inorganic acid such as concentrated sulfuric acid
- the reaction can be carried out using an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide in alcohol, for example. It is preferable to carry out the reaction under heating and reflux.
- the compound represented by the general formula (4) is also a novel compound, and the compound represented by the general formula (2) is reacted with the compound represented by the general formula (3) or the compound represented by the general formula (3—a) Can be produced by reacting the compound represented by the formula after deprotection.
- R is as described above, and B 0 c is a Yuichi Sharytoxoxycarbyl group.
- reaction is carried out according to a conventional method in the presence of an inorganic base or an organic base, by the general formula
- the compound represented by the general formula (3) is reacted with the compound represented by the general formula (3) or the protective group of the compound represented by the general formula (3-a) is reacted with trifluoroacetic acid or the like. It can be carried out by deprotecting by treating and reacting with a compound represented by the general formula (2).
- the compound represented by (3) can be used for the next reaction without isolation after the deprotection reaction.
- the base an organic base such as triethylamine is preferable.
- N N-dimethyl
- An inert solvent such as tilformamide, dimethylsulfoxide or N-methyl-1-pyrrolidone can be used.
- the reaction temperature is from room temperature to 200 ° C, preferably.
- the mixture is heated and stirred at ioo ° c to i50 ° c.
- the compounds of the present invention include optical isomers based on the asymmetric carbon at the 3-position of pyrrolidine, and these are all included. Furthermore, the compounds of the present invention also include hydrates, all of which are included in the scope of the present invention.
- Example 3 4- [3 (R)-(3-chlorobenzyloxy) pyrrolidine-111] obtained in Example 3 1,2,2-diphenylbutyronitrile 8.93 Using g, the same operation as in Example 9 was carried out to obtain 7.88 g of the desired product as an oil.
- Example 4 was repeated using 460 mg of 4_ [3 (S)-(3-chlorobenzyloxy) pyrrolidine-111]-[2,2-diphenylbutyronitrile] obtained in Example 4. The same operation was carried out to obtain 4i3mg of the desired product as an oil.
- Action of the test agent indicates in p A 2 as determined by Shirudopuro' bets from the degree of rightward movement of the concentration-response curve of Asechirukorin 1 ⁇ 9 ⁇ 3 xlO- 6 M o
- the compound of the present invention exhibited excellent anticholinergic activity, and exhibited an effect of suppressing the amount of defecation based on the action.
- the compounds of the present invention showed higher selectivity for muscular phosphorous receptors in the ileum than in cardiac muscle.
- the compound of the present invention is effective for the treatment of irritable bowel syndrome and the like, has high organ selectivity, and is useful as a drug having few side effects on the heart and pupils.
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0001118A HUP0001118A3 (en) | 1996-12-02 | 1997-11-26 | N-substituted pyrrolidine derivatives, process for preparing the same and pharmaceutical compositions containing them |
CA002273253A CA2273253C (en) | 1996-12-02 | 1997-11-26 | Novel n-substituted pyrrolidine derivatives and process for preparing the same |
AT97913443T ATE235903T1 (de) | 1996-12-02 | 1997-11-26 | Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren |
JP52543998A JP4167302B2 (ja) | 1996-12-02 | 1997-11-26 | 新規n―置換ピロリジン誘導体及びその製造法 |
AU50669/98A AU733209B2 (en) | 1996-12-02 | 1997-11-26 | Novel n-substituted pyrrolidine derivatives and process for preparing the same |
EP97913443A EP0948964B1 (en) | 1996-12-02 | 1997-11-26 | Novel n-substituted pyrrolidine derivatives and process for preparing the same |
KR10-1999-7004870A KR100483221B1 (ko) | 1996-12-02 | 1997-11-26 | N-치환된 피롤리딘 유도체 및 이의 제조방법 |
DE69720518T DE69720518T2 (de) | 1996-12-02 | 1997-11-26 | Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren |
US09/308,661 US6071950A (en) | 1996-12-02 | 1997-11-26 | N-substituted pyrrolidine derivatives and process for preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33635396 | 1996-12-02 | ||
JP8/336353 | 1996-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998024431A1 true WO1998024431A1 (fr) | 1998-06-11 |
Family
ID=18298258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004306 WO1998024431A1 (fr) | 1996-12-02 | 1997-11-26 | Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives |
Country Status (12)
Country | Link |
---|---|
US (1) | US6071950A (ja) |
EP (1) | EP0948964B1 (ja) |
JP (1) | JP4167302B2 (ja) |
KR (1) | KR100483221B1 (ja) |
CN (1) | CN1104239C (ja) |
AT (1) | ATE235903T1 (ja) |
AU (1) | AU733209B2 (ja) |
CA (1) | CA2273253C (ja) |
DE (1) | DE69720518T2 (ja) |
HU (1) | HUP0001118A3 (ja) |
TW (1) | TW429249B (ja) |
WO (1) | WO1998024431A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1928821B1 (en) * | 2005-09-21 | 2009-01-07 | Pfizer Limited | Carboxamide derivatives as muscarinic receptor antagonists |
WO2008035157A1 (en) * | 2006-09-22 | 2008-03-27 | Pfizer Limited | Azetidine derivatives as muscarinic receptor antagonists |
ES2364727T3 (es) | 2007-03-16 | 2011-09-13 | Pfizer Limited | Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02282360A (ja) * | 1989-03-17 | 1990-11-19 | Pfizer Inc | ピロリジン誘導体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006536A1 (en) * | 1989-10-25 | 1991-05-16 | The Regents Of The University Of California | Method of inhibiting the transport of l-glutamate |
GB8928042D0 (en) * | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
IL117440A0 (en) * | 1995-03-31 | 1996-07-23 | Pfizer | Pyrrolidinyl hydroxamic acid compounds and their production process |
DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
AU746126B2 (en) * | 1997-09-08 | 2002-04-18 | Georgetown University | Substituted 2-pyrrolidinone activators of PKC |
JPH11100366A (ja) * | 1997-09-29 | 1999-04-13 | Kyorin Pharmaceut Co Ltd | 新規n−置換環状アミン誘導体及びその製造法 |
-
1997
- 1997-11-26 DE DE69720518T patent/DE69720518T2/de not_active Expired - Fee Related
- 1997-11-26 US US09/308,661 patent/US6071950A/en not_active Expired - Fee Related
- 1997-11-26 CN CN97180257A patent/CN1104239C/zh not_active Expired - Fee Related
- 1997-11-26 AU AU50669/98A patent/AU733209B2/en not_active Ceased
- 1997-11-26 HU HU0001118A patent/HUP0001118A3/hu unknown
- 1997-11-26 WO PCT/JP1997/004306 patent/WO1998024431A1/ja active IP Right Grant
- 1997-11-26 KR KR10-1999-7004870A patent/KR100483221B1/ko not_active IP Right Cessation
- 1997-11-26 AT AT97913443T patent/ATE235903T1/de not_active IP Right Cessation
- 1997-11-26 EP EP97913443A patent/EP0948964B1/en not_active Expired - Lifetime
- 1997-11-26 JP JP52543998A patent/JP4167302B2/ja not_active Expired - Fee Related
- 1997-11-26 CA CA002273253A patent/CA2273253C/en not_active Expired - Fee Related
- 1997-11-28 TW TW086117933A patent/TW429249B/zh not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02282360A (ja) * | 1989-03-17 | 1990-11-19 | Pfizer Inc | ピロリジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
HUP0001118A3 (en) | 2001-06-28 |
ATE235903T1 (de) | 2003-04-15 |
EP0948964B1 (en) | 2003-04-02 |
EP0948964A4 (en) | 2001-04-04 |
JP4167302B2 (ja) | 2008-10-15 |
CA2273253C (en) | 2003-09-16 |
DE69720518D1 (de) | 2003-05-08 |
CN1239428A (zh) | 1999-12-22 |
KR20000069260A (ko) | 2000-11-25 |
CA2273253A1 (en) | 1998-06-11 |
KR100483221B1 (ko) | 2005-04-15 |
CN1104239C (zh) | 2003-04-02 |
TW429249B (en) | 2001-04-11 |
AU5066998A (en) | 1998-06-29 |
AU733209B2 (en) | 2001-05-10 |
EP0948964A1 (en) | 1999-10-13 |
HUP0001118A2 (hu) | 2000-10-28 |
DE69720518T2 (de) | 2004-02-26 |
US6071950A (en) | 2000-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU766233B2 (en) | Substituted imidazolidinone derivatives | |
FI95027B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-substituoitujen pyrrolidiinijohdannaisten valmistamiseksi | |
JPH07119213B2 (ja) | ムスカリンリセプターアンタゴニスト | |
AU2013369649A1 (en) | Heterocyclic compounds and methods of use thereof | |
BRPI0808758A2 (pt) | Derivados de benzamida e processo para o preparo dos mesmos | |
WO2023023347A1 (en) | Prodrugs and derivatives of psilocin and uses thereof | |
JP4115522B2 (ja) | 新規な5−アミノサリチル酸のアゾ誘導体 | |
JPH0977742A (ja) | 新規なベンズアミド誘導体 | |
US5250537A (en) | 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole,-6,7,8,9,10-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives | |
PT741734E (pt) | Complexos de acido fenilboronico | |
WO1998024431A1 (fr) | Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives | |
TWI375557B (en) | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane | |
JPH08503229A (ja) | Gaba−bアンタゴニストとしての2−置換モルホリンおよびチオモルホリン誘導体 | |
US5643917A (en) | 4-aminomethyl-1-azaadamantane derived benzamides | |
JPH11100366A (ja) | 新規n−置換環状アミン誘導体及びその製造法 | |
TW479057B (en) | 5,11-dihydrobenzo[b,e] [1,4]oxazepine derivatives and pharmaceutical composition containing the same | |
JPH0373551B2 (ja) | ||
JP3694774B2 (ja) | フェニルカルボン酸誘導体 | |
WO2000056718A1 (fr) | Composes a base d'imidazole | |
WO2009033360A1 (fr) | Dérivés de benzamide, leur préparation et leurs utilisations pour un médicament | |
US5424424A (en) | Tartaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
JPH0342276B2 (ja) | ||
WO1995025100A1 (fr) | Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes | |
JPH0414112B2 (ja) | ||
WO1996003403A1 (de) | Benzylimidazopyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97180257.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2273253 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997913443 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 50669/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997004870 Country of ref document: KR Ref document number: 09308661 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997913443 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997004870 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 50669/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997913443 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997004870 Country of ref document: KR |